scholarly journals Tissue-type plasminogen activator and its inhibitor(PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus(NIDDM).

1990 ◽  
Vol 27 (6) ◽  
pp. 699-705 ◽  
Author(s):  
Hiroshi Jokaji ◽  
Hidesaku Asakura ◽  
Masanori Saito ◽  
Chika Uotani ◽  
Ichiro Kumabashiri ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasminogen Activator ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Tissue Type ◽  
Dependent Diabetes Mellitus ◽  
Tissue Type Plasminogen Activator ◽  
Type Plasminogen Activator ◽  
Insulin Dependent ◽  
Pai 1

Plasminogen Activator Inhibitor Type-1 (PAI-1) Levels Are Decreased in NIDDM Patients treated with Insulin

1998 ◽  
Vol 4 (2) ◽  
pp. 138-139
Author(s):  
Peter Galajda ◽  
Emil Martinka ◽  
Ján Staško ◽  
Marian Mokáň ◽  
Peter Kubisz
Keyword(s):  
Diabetes Mellitus ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Insulin Dependent ◽  
Niddm Patients ◽  
Activator Inhibitor ◽  
Pai 1

We examined 25 non-insulin-dependent diabetes mellitus (NIDDM) patients treated with sulfonylurea (SU) regi mens, 14 NIDDM patients with 8-12 weeks long-acting insulin (INS) treatment and 15 age-matched normoinsulinemic healthy controls. Plasminogen activator inhibitor-1 (PAI-1) levels were significantly increased in NIDDM patients treated by SU agents (median 58.9, range 14-217 ng/ml) compared to patients with insulin therapy (median 20.7, 4-53 ng/ml) and normal controls (median 10.8, 4-52 ng/ml) (p < 0.001). Non-insulin- dependent diabetes mellitus subgroups were not different in other hemostatic (von Willebrand factor, thrombomodulin, tis sue factor pathway inhibitor, platelet factor-4 levels) and meta bolic (C-peptide, triglycerides) parameters and PAI-1 levels did not correlate with these hemostatic and metabolic parameters. This finding suggests that insulin application itself may cause decreased PAI-1 levels, probably by influence on intracellular calcium. This hypothesis requires further research. Key Words: PAI-1—Insulin treatment—Non—insulin—dependent diabetes mellitus.

Elevated Circulating P-Selectin in Insulin Dependent Diabetes Mellitus

1996 ◽  
Vol 76 (03) ◽  
pp. 328-332 ◽  
Author(s):  
Bernd Jilma ◽  
Peter Fasching ◽  
Christine Ruthner ◽  
Anna Rumplmayr ◽  
Sabine Ruzicka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Insulin Dependent Diabetes Mellitus ◽  
Interquartile Range ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Intergroup Comparison ◽  
Median Plasma ◽  
Insulin Dependent

SummaryBased on findings that showed increased P-selectin expression on platelets and on choroidal microvessels of patients with insulin dependent diabetes mellitus (IDDM), we hypothesized that also plasma concentrations of circulating (c)P-selectin would be increased in these patients.The aim of this study was to compare the plasma levels of cP-selec-tin between non-smoking patients with IDDM, treated with an intensified insulin therapy, and healthy controls. The study design was prospective, cross-sectional and analyst-blinded. Subjects were matched individually for sex, age and body mass index. Plasma levels of cP-selectin and of von Willebrand antigen (vWF-Ag) were determined by enzyme linked immunoassays.Forty-two pairs were available for intergroup comparison. Median plasma concentrations of cP-selectin in patients with IDDM (285 ng/ml; interquartile range: 233-372) were on average 21% higher than those of controls (236 ng/ml; interquartile range: 175-296; p = 0.004). Also, median plasma levels of vWF-Ag were 10% higher in patients (96 U/dl; interquartile range: 82-127) than controls (87 U/dl; interquartile range: 70-104; p = 0.025). There was no correlation between plasma concentrations of cP-selectin and vWF-Ag levels in either group (p ώ0.05).In conclusion, our results of increased cP-selectin levels are in line with increased P-selectin expression on platelets and on choroidal microvessels found in patients with IDDM. In view of the currently developed small molecule inhibitors of cell adhesion molecules, these independent observations together may provide a sound rationale to select P-selectin as a target for treating or preventing IDDM-associated micro- or macrovascular complications.

Sign in / Sign up

Export Citation Format

Share Document